Sales of interleukin inhibitors that are used to treat autoimmune diseases such as psoriasis have increased over twofold in 2 years. 1st generation drugs including Stelara, Cosentyx, Tremfya, and Skyrizi have all shown even growth. Market analysts have evaluated that the use of IL inhibitors has increased with the steady expansion of their indications.

According to the market research institution IQVIA on the 27th, the IL-17/23 inhibitor class market size had increased 41.4% YoY to reach ₩28.7 billion in Q1 this year.

IL inhibitors, which are mainly used to treat psoriasis, can be classified into IL-17 and IL-23 class drugs. The first mover in the market, Stelara concurrently targets I